Statin use reduces cataract & AMD risk

Article

Statins may have protective effects on the development of both cataract and age-related macular degeneration (AMD), according to a report published in the April issue of the American Journal of Ophthalmology.

Statins may have protective effects on the development of both cataract and age-related macular degeneration (AMD), according to a report published in the April issue of the American Journal of Ophthalmology.

Jennifer Tan and colleagues from the Centre for Vision Research, University of Sydney, Australia examined the relationship between statin use and long-term incidence of cataract and AMD using participants from the Blue Mountains Eye Study.

A total of 2,335 participants were re-examined at five years and 1,952 at 10 years. After controlling for age and gender, compared with non-users, statin users had a reduced risk of developing indistinct soft drusen, the principal late AMD precursor lesion (hazard ratio, 0.33; 95% confidence interval, 0.13 to 0.84).

The authors also discovered that statin use can reduce the risk of cataract development by up to 50%.

Recent Videos
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
© 2024 MJH Life Sciences

All rights reserved.